Breaking News
Get 45% Off 0
🌊 NVIDIA ripple effect: Track AI stocks' response to chip giant's earnings
Explore AI Stocks

OPKO's BioReference Laboratories Offers COVID-19 Testing (Revised)

By Zacks Investment ResearchStock MarketsMar 25, 2020 02:26AM ET
www.investing.com/analysis/opkos-bioreference-laboratories-offers-covid19-testing-revised-200518748
OPKO's BioReference Laboratories Offers COVID-19 Testing (Revised)
By Zacks Investment Research   |  Mar 25, 2020 02:26AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
 
BDX
-1.01%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
SYK
+0.67%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
OPK
+1.22%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
PRAH
0.00%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
OPKO Health, Inc. (OPK) recently announced that its subsidiary — BioReference Laboratories — has collaborated with the state of New Jersey to provide coronavirus (COVID-19) testing across the state.
Notably, BioReference Laboratories will initially provide testing for facilities at Burlington, Essex, Hudson, Ocean and Union Counties.
For investors’ notice, BioReference Laboratories provides the detection, diagnosis, evaluation, monitoring and treatment of diseases. Hence, the latest move is likely to boost OPKO’s foothold in the global infectious disease diagnostics market.
More on the News
It is encouraging to note that given the widespread COVID-19 outbreak, OPKO’s BioReference Laboratories is currently accepting specimens for COVID-19 testing from healthcare providers, clinics and health systems throughout the United States.
Notably, test developers are getting approvals through Emergency Use Authorization for their tests to be used in Clinical Laboratory Improvement Amendments (CLIA)- certified laboratories. As a CLIA-certified laboratory, BioReference Laboratories has been utilizing several different testing platforms to increase its COVID-19 testing capacity.
Market Prospects
A report by MarketsandMarkets projects the global infectious disease diagnostics market to reach a worth of $19.35 billion in 2022, at a CAGR of 5.6%.
Hence, the latest development has been a well-timed one for OPKO.
COVID-19 Wreaks Havoc
The COVID-19 pandemic has devastated the world. Notably, the United States is currently witnessing 35,070 cases, with the death toll rising to 458.
Given this grim backdrop, U.S. MedTech players are trying to ramp up testing to check the spread of the pandemic.
For instance, Becton, Dickinson and Company (BDX) has recently announced the submission of EUA requests to the FDA for diagnostic tests. Notably, the tests, if authorized, would increase the potential capacity for COVID-19 screening by 1,000 per day. That’s not all. The company has also announced the receipt of the CE mark for the VIASURE SARS-CoV-2 real-time test adapted for the BD MAX System. Notably, the test, used to detect COVID-19, is now available to clinical laboratories.
Further, PRAH Health Sciences (PRAH) recently announced the commercial availability of the COVID-19 Monitoring Program, a mobile app that allows employers, payers, providers and health systems to track the health and wellbeing of individuals.
A Key Pick
A better-ranked stock in the broader medical space is Stryker Corporation (SYK).
Stryker’s long-term earnings growth is expected at 10.1%. The stock currently has a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
(We are reissuing this article to correct a mistake. The original article, issued on March 23, 2020, should no longer be relied upon.)
OPKO Health, Inc. (NASDAQ:OPK) recently announced that its subsidiary — BioReference Laboratories — has collaborated with the state of New Jersey to provide coronavirus (COVID-19) testing across the state.
Notably, BioReference Laboratories will initially provide testing for facilities at Burlington, Essex, Hudson, Ocean and Union Counties.
For investors’ notice, BioReference Laboratories provides the detection, diagnosis, evaluation, monitoring and treatment of diseases. Hence, the latest move is likely to boost OPKO’s foothold in the global infectious disease diagnostics market.
More on the News
It is encouraging to note that given the widespread COVID-19 outbreak, OPKO’s BioReference Laboratories is currently accepting specimens for COVID-19 testing from healthcare providers, clinics and health systems throughout the United States.
Notably, test developers are getting approvals through Emergency Use Authorization for their tests to be used in Clinical Laboratory Improvement Amendments (CLIA)- certified laboratories. As a CLIA-certified laboratory, BioReference Laboratories has been utilizing several different testing platforms to increase its COVID-19 testing capacity.
Market Prospects
A report by MarketsandMarkets projects the global infectious disease diagnostics market to reach a worth of $19.35 billion in 2022, at a CAGR of 5.6%.
Hence, the latest development has been a well-timed one for OPKO.
COVID-19 Wreaks Havoc
The COVID-19 pandemic has devastated the world. Notably, the United States is currently witnessing 35,070 cases, with the death toll rising to 458.
Given this grim backdrop, U.S. MedTech players are trying to ramp up testing to check the spread of the pandemic.
For instance, Becton, Dickinson and Company (NYSE:BDX) has recently announced the submission of EUA requests to the FDA for diagnostic tests. Notably, the tests, if authorized, would increase the potential capacity for COVID-19 screening by 1,000 per day. That’s not all. The company has also announced the receipt of the CE mark for the VIASURE SARS-CoV-2 real-time test adapted for the BD MAX System. Notably, the test, used to detect COVID-19, is now available to clinical laboratories.
Further, PRAH Health Sciences (NASDAQ:PRAH) recently announced the commercial availability of the COVID-19 Monitoring Program, a mobile app that allows employers, payers, providers and health systems to track the health and wellbeing of individuals.
A Key Pick
A better-ranked stock in the broader medical space is Stryker Corporation (NYSE:SYK) .
Stryker’s long-term earnings growth is expected at 10.1%. The stock currently has a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
(We are reissuing this article to correct a mistake. The original article, issued on March 23, 2020, should no longer be relied upon.)


Becton, Dickinson and Company (BDX): Free Stock Analysis Report

Stryker Corporation (SYK): Free Stock Analysis Report

OPKO Health, Inc. (OPK): Free Stock Analysis Report

PRA Health Sciences, Inc. (PRAH): Free Stock Analysis Report

Original post

Zacks Investment Research
OPKO's BioReference Laboratories Offers COVID-19 Testing (Revised)
 

Related Articles

OPKO's BioReference Laboratories Offers COVID-19 Testing (Revised)

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email